公众号 / 文章呼吸衰竭与机械通气消化、代谢与肾脏急症

79岁女性晚期肺癌伴双肺浸润

A 79-Year-Old Woman With Advanced Lung Carcinoma and Bilateral Infiltrates.
PubMed 文献 · Chest · 2022-01-01
一句话结论奥希替尼治疗14个月后出现缓慢进展的呼吸困难与严重低氧血症,需考虑药物相关肺损伤。

本文报告一例79岁女性,因进行性呼吸困难和严重低氧血症入院,需氧疗。患者14个月前因EGFR外显子19缺失肺腺癌伴骨、脑转移开始奥希替尼治疗,同时因首次肺栓塞服用利伐沙班。近数月用药无变化、未用抗生素,无有毒烟雾或物质暴露史,不吸烟,家族史无自身免疫病或间质性肺病。文章围绕晚期肺癌患者出现双肺浸润的鉴别诊断展开。

要点

  • 79岁女性,EGFR外显子19缺失肺腺癌伴骨、脑转移,奥希替尼治疗14个月后出现进行性呼吸困难和严重低氧血症。
  • 呼吸困难约在就诊前3至4周开始,此后数周缓慢进展。
  • 近数月用药无变化,未使用抗生素,无有毒烟雾或物质暴露史,不吸烟。
  • 家族史无自身免疫病或间质性肺病,因首次肺栓塞服用利伐沙班。

适用人群与场景

  • 79岁女性,EGFR外显子19缺失肺腺癌伴骨、脑转移,奥希替尼治疗14个月,因首次肺栓塞服用利伐沙班。

研究设计与关键结果

  • 病例报告:79岁女性因进行性呼吸困难和严重低氧血症入院,需氧疗;呼吸困难约在就诊前3至4周开始,此后数周缓慢进展。
  • 患者14个月前因EGFR外显子19缺失肺腺癌伴骨、脑转移开始奥希替尼治疗;因首次肺栓塞服用利伐沙班。
  • 就诊前数月用药无变化、未使用抗生素,无有毒烟雾或物质暴露史,不吸烟,家族史无自身免疫病或间质性肺病。

证据类型、等级与局限

  • 病例报告。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

A 79-year-old woman was admitted to the hospital for progressive dyspnea and severe hypoxemia, requiring oxygen supplementation. The dyspnea started approximately 3 to 4 weeks before presentation and was slowly progressive throughout the following weeks. Her medical history mentioned an adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 deletion of the lung with metastases to the bones and brain for which treatment with osimertinib was started 14 months earlier. Furthermore, she was treated with rivaroxaban for a first episode of a pulmonary embolism. In the months leading up to her current presentation there were no changes in medication and no use of antibiotics. She had no known exposure to toxic fumes or substances, she was a nonsmoker, and her family history was unremarkable for autoimmune disorders or interstitial lung disease (ILD).

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Jager EC, de Boer WS, van Schaik ML, et al. A 79-Year-Old Woman With Advanced Lung Carcinoma and Bilateral Infiltrates. Chest. 2022. PMID: 35680315. doi:10.1016/j.chest.2022.01.043

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。